What kind of drug is Bikken Pronol Tablets (Bituowei) and analysis of its main indications

Biktarvy tablets (Biktarvy) is a compound oral antiviral drug that belongs to antiretroviral therapy (ART) drugs and is used for the management of HIV infection. The drug consists of three active ingredients: Bictegravir (Bictegravir), tenofovir alafenamide (TAF) and emtricitabine (Emtricitabine). Bictavir is an integrase inhibitor (INSTI) that can block HIV virusDNA< span> is integrated into the host genome, thereby inhibiting viral replication; tenofovir alafenamide and emtricitabine are nucleoside reverse transcriptase inhibitors (NRTIs), which further inhibit viral replication by blocking the activity of viral reverse transcriptase.

Bikernoprenol tablets are mainly used to treat HIV-1 infected adults and adolescent patients (12 years old and above, weighing at least 35kg). It can be used both in treatment-naive patients and in patients who have already experienced antiretroviral treatment, but it is necessary to ensure that the patient's virus is not resistant to the drug components. Through the synergistic effect of three drugs, Biktarvy can effectively suppress HIV viral load, achieve virological control, improve immune function, and delay the occurrence of AIDS-related complications.

Clinical studies have shown that Biktarvy is highly effective and durable in suppressing HIV viral load. After use, most patients can reach undetectable viral levels within 24 weeks to 48 weeks, and the drug is well tolerated. Compared with traditional multi-drug combination regimens, Biktarvy only needs to be taken once a day, simplifying the medication process and improving patient compliance. In addition, the drug has relatively little impact on kidneys and bone density, making it suitable for long-term maintenance treatment.

UsingBiktarvy should be done under the guidance of a doctor, and avoid adjusting the dosage or stopping the drug on your own to prevent viral resistance. Patients need to be tested for HIV before treatmentDrug resistance genotype and liver and kidney function. Viral load, CD4 count and liver and kidney indicators should be reviewed regularly during long-term medication. For pregnant women, lactating women, or patients with hepatic and renal insufficiency, the medication regimen should be evaluated individually. In addition, simultaneous use with potent CYP3A or UGT1A1 inducers that may affect drug metabolism should be avoided to ensure drug efficacy and safety.

Reference materials:https://www.drugs.com/